Arcellx, Inc.
ACLX
Updated: 24/09/2026, 06:01:14
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
No summaries found.
- Share price
- $115.07
- Market cap
- $6.73B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Rami Elghandour
- Employees
- 163
- IPO date
- 04/02/2022
- Beta
- 0.248
- Last dividend
- $0.00
- Day range
- $115.03 – $115.07
- 52-week range
- $50.85 – $115.13
- 1-day performance
- 0.02%
- 1-year performance
- 126.29%
- Current drawdown (1Y)
- -0.05%
- CIK
- 0001786205
- CUSIP
- 03940C100
- ISIN
- US03940C1009
- Created
- 07/12/2025, 01:54:37
- Last update
- 24/09/2026, 06:01:14
Track Arcellx, Inc. with an AI analyst
See which prediction-market events move ACLX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Zacks Investment Research • STOCK • 13/03/2026, 12:11:08
Baron Health Care Fund Q4 2025 Contributors And Detractors
Seeking Alpha • STOCK • 03/03/2026, 11:18:00
Understanding Arcellx Inc (ACLX)'s Financial Health and Market Position
Market Data • Market Data • 26/02/2026, 06:13:18
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Business Wire • STOCK • 23/02/2026, 20:21:00
Arcellx, Inc. (NASDAQ: ACLX) Acquisition by Gilead Sciences: A Strategic Move in Biotechnology
Market Data • Market Data • 23/02/2026, 18:15:40
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX)
PRNewsWire • STOCK • 23/02/2026, 16:00:00
Here's Why Shares of Arcellx Are Up Almost 80% Today
Investopedia • STOCK • 23/02/2026, 15:25:52
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders
PRNewsWire • STOCK • 23/02/2026, 12:39:00
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders
PRNewsWire • STOCK • 23/02/2026, 12:00:00
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Invezz • STOCK • 23/02/2026, 09:41:56
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
WSJ • STOCK • 23/02/2026, 07:36:00
Gilead to acquire Arcellx for $7.8 billion
Reuters • STOCK • 23/02/2026, 07:08:19